Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Interest & Investment Income (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Interest & Investment Income data on record, last reported at $205000.0 in Q4 2025.

  • For Q4 2025, Interest & Investment Income changed 0.0% year-over-year to $205000.0; the TTM value through Dec 2025 reached $929000.0, down 34.44%, while the annual FY2025 figure was $929000.0, 34.44% down from the prior year.
  • Interest & Investment Income reached $205000.0 in Q4 2025 per VRCA's latest filing, up from $159000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $822000.0 in Q3 2023 and bottomed at $20000.0 in Q2 2022.
  • Average Interest & Investment Income over 5 years is $284250.0, with a median of $213000.0 recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: surged 3030.0% in 2023, then plummeted 74.12% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $27000.0 in 2021, then surged by 959.26% to $286000.0 in 2022, then skyrocketed by 176.92% to $792000.0 in 2023, then tumbled by 74.12% to $205000.0 in 2024, then changed by 0.0% to $205000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $205000.0 in Q4 2025, $159000.0 in Q3 2025, and $228000.0 in Q2 2025.